Tirzepatide, a dual GLP-1/GIP receptor agonist approved as Mounjaro for diabetes and Zepbound for weight management, has demonstrated superior efficacy compared to semaglutide in head-to-head trials (SURPASS-2 for diabetes
DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V (2020) Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
Its important to talk with a healthcare provider about how long to use these medicines and make long-term healthy lifestyle changes to help keep weight off for good
In October 2023, the European Medicines Agency gave a big update on semaglutide for hypothyroidism
Urine and faeces were shown to be important routes of excretion, with urine as the primary route in both humans and animals[1]